Karnataka Antibiotics And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
- Paid Up Capital ₹ 13.49 Cr
- Company Age 43 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.25 Cr
- Satisfied Charges ₹ 42.06 Cr
- Revenue Growth 11.12%
- Profit Growth 6.36%
- Ebitda 8.34%
- Net Worth 9.19%
- Total Assets 16.41%
About Karnataka Antibiotics And Pharmaceuticals
Karnataka Antibiotics And Pharmaceuticals Limited (KAAPL) is a leading Public Limited Union Government Company incorporated in India on 13 March 1981 and has a history of 43 years and 11 months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 13.49 Cr.
The company currently has active open charges totaling ₹21.25 Cr. The company has closed loans amounting to ₹42.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Karnataka Antibiotics And Pharmaceuticals Limited India are Supriya Kulkarni as COMPANY SECRETARY and Ramesha Bajakudlu as Cfo. Satheesha Chandrappa, Vijay Srivastava, Madhuchanda Kar, and Four other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231KA1981GOI004145
- Company No.
004145
- Company Classification
Public Limited Union Government Company
- Incorporation Date
13 Mar 1981
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Karnataka Antibiotics And Pharmaceuticals Limited offer?
Karnataka Antibiotics And Pharmaceuticals Limited offers a wide range of products and services, including Common Disease Medicines, Injectable Products, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs.
Who are the key members and board of directors at Karnataka Antibiotics And Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Supriya Kulkarni | Company Secretary | 01-Feb-2020 | Current |
| Ramesha Bajakudlu | CFO | 23-Dec-2024 | Current |
Nirja Saraf  | Managing Director | 26-Mar-2024 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satheesha Chandrappa | Nominee Director | 01-Feb-2024 | Current |
| Vijay Srivastava | Nominee Director | 22-Jun-2023 | Current |
| Madhuchanda Kar | Director | 24-Feb-2022 | Current |
| Tayappa Bhagoji | Nominee Director | 03-Nov-2020 | Current |
| Thichempully Kumar | Nominee Director | 25-Oct-2021 | Current |
| Harsh Gupta | Director | 23-Jul-2024 | Current |
Financial Performance of Karnataka Antibiotics And Pharmaceuticals.
Karnataka Antibiotics And Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.12% increase. The company also saw a slight improvement in profitability, with a 6.36% increase in profit. The company's net worth moved up by a moderate rise of 9.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karnataka Antibiotics And Pharmaceuticals?
In 2021, Karnataka Antibiotics And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bengal Chemicals And Pharmaceuticals LtdVijay Srivastava and Nirja Saraf are mutual person
Karnataka State Medical Supplies Corporation LimitedThichempully Kumar and Harsh Gupta are mutual person
Hindustan Antibiotics LimitedNirja Saraf is a mutual person
Tadadi Eco-Tourism Infrastructure LimitedSatheesha Chandrappa is a mutual person
- Ksiidc - Il&Fs Project Development Company Limited
Satheesha Chandrappa is a mutual person
Charges (Loans)
₹21.25 Cr
₹42.06 Cr
Charges Breakdown by Lending Institutions
- Vijaya Bank : 13.90 Cr
- State Bank Of India : 7.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Nov 2005 | Vijaya Bank | ₹13.90 Cr | Open |
| 06 May 2002 | State Bank Of India | ₹7.35 Cr | Open |
| 11 May 2017 | Vijaya Bank | ₹15.00 Cr | Satisfied |
| 30 Apr 2010 | Vijaya Bank | ₹8.00 Cr | Satisfied |
| 29 Mar 2006 | Vijaya Bank | ₹7.00 Cr | Satisfied |
How Many Employees Work at Karnataka Antibiotics And Pharmaceuticals?
Karnataka Antibiotics And Pharmaceuticals has a workforce of 860 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karnataka Antibiotics And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karnataka Antibiotics And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
